Stage III pancreatic cancer and the role of irreversible electroporation

• Published in: BMJ (Online) Vol. 350; no. mar18 11; p. h521
• Main Authors: Al Efishat, Mohammad, Wolfgang, Christopher L, Weiss, Matthew J
• Format: Journal Article Book Review
• Language: English
• Published: England British Medical Journal Publishing Group 18-03-2015; BMJ Publishing Group LTD
• Subjects: Ablation Techniques; Adenocarcinoma - epidemiology; Adenocarcinoma - pathology; Adenocarcinoma - therapy; Chemotherapy, Adjuvant; Electroporation - methods; Humans; Neoadjuvant Therapy; Neoplasm Staging; Pancreatectomy; Pancreatic cancer; Pancreatic Neoplasms - epidemiology; Pancreatic Neoplasms - pathology; Pancreatic Neoplasms - therapy; Radiotherapy, Adjuvant; STATE OF THE ART REVIEW
• ISSN: 0959-8138; 1756-1833; 1756-1833
• DOI: 10.1136/bmj.h521

About a third of patients with pancreatic cancer present with locally advanced disease that is not amenable to resection. Because these patients have localized disease, conventional ablative therapies (thermal ablation and cryoablation) have the potential to be beneficial, but their use is inherently limited in the pancreas. These limitations could be overcome by irreversible electroporation—a novel, non-thermal ablative method that is gaining popularity for the treatment of many soft tissue tumors, including those of the pancreas. This review summarizes the status of this technique in the treatment of locally advanced pancreatic cancer. Most of the evidence on efficacy and safety is based on non-randomized prospective series, which show that irreversible electroporation may improve overall survival and pain control in locally advanced pancreatic cancer. As experience with this procedure increases, randomized controlled trials are needed to document its efficacy in locally advanced pancreatic cancer more precisely.